Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...
Even Kennedy acknowledges that there isn’t robust scientific data to support the use of these peptides.
Unlike tablets, which stay inside the body of the person taking them, topical drugs are absorbed through the skin - and they ...
The GLP‑1 beverage market is accelerating fast, with brands innovating in hydration, protein, fibre and collagen to meet ...
The boy’s father, Arturo Bazan, adoptive mother Dulce Bazan and older brother Carlos Hernandez-Bazan, 25, are charged with ...
On the occasion of International Women's Day, Outlook Business in an exclusive interview features Saloni Anand, co-founder of ...
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone ...
Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results